Jilin Zhongbang Meitai Biopharmaceutical

Jilin Zhongbang Meitai Biopharmaceutical is a Chinese biotechnology company headquartered in Changchun, specializing in the research, development, and large-scale production of recombinant protein therapeutics. The company's commercial portfolio is centered on essential cytokines and growth factors, including recombinant human granulocyte colony-stimulating factor (rhG-CSF) and recombinant human interleukin-2 (rhIL-2). These products are primarily utilized in oncology to manage chemotherapy-induced side effects and as immunotherapy for various cancers. Zhongbang Meitai operates advanced GMP-certified manufacturing facilities and maintains a strong focus on the domestic Chinese biopharmaceutical market.